How to buy Akcea Therapeutics stock

Akcea Therapeutics, Inc is a biotechnology business based in the US. Akcea Therapeutics shares (AKCA) are listed on the NASDAQ and all prices are listed in US Dollars. Akcea Therapeutics employs 294 staff and has a trailing 12-month revenue of around USD$336.6 million.

How to buy shares in Akcea Therapeutics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Akcea Therapeutics. Find the stock by name or ticker symbol: AKCA. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Akcea Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Akcea Therapeutics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Akcea Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Akcea Therapeutics share price

Use our graph to track the performance of AKCA stocks over time.

Akcea Therapeutics shares at a glance

• Key figures

Information last updated 2021-01-22.

52-week range	USD$8 - USD$18.57
50-day moving average	USD$18.1414
200-day moving average	USD$14.8534
Wall St. target price	USD$28.5
PE ratio	39.9101
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$0.286

Buy Akcea Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Akcea Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Akcea Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Akcea Therapeutics financials

Revenue TTM	USD$336.6 million
Gross profit TTM	USD$185.7 million
Return on assets TTM	-5.95%
Return on equity TTM	0%
Profit margin	-12.34%
Book value	$4.719
Market capitalisation	USD$1.8 billion

TTM: trailing 12 months

Shorting Akcea Therapeutics shares

There are currently 759,276 Akcea Therapeutics shares held short by investors – that's known as Akcea Therapeutics's "short interest". This figure is 34.8% down from 1.2 million last month.

There are a few different ways that this level of interest in shorting Akcea Therapeutics shares can be evaluated.

Akcea Therapeutics's "short interest ratio" (SIR)

Akcea Therapeutics's "short interest ratio" (SIR) is the quantity of Akcea Therapeutics shares currently shorted divided by the average quantity of Akcea Therapeutics shares traded daily (recently around 1.1 million). Akcea Therapeutics's SIR currently stands at 0.68. In other words for every 100,000 Akcea Therapeutics shares traded daily on the market, roughly 680 shares are currently held short.

However Akcea Therapeutics's short interest can also be evaluated against the total number of Akcea Therapeutics shares, or, against the total number of tradable Akcea Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Akcea Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Akcea Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.0597% of the tradable shares (for every 100,000 tradable Akcea Therapeutics shares, roughly 60 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Akcea Therapeutics.

Find out more about how you can short Akcea Therapeutics stock.

Akcea Therapeutics share price volatility

Over the last 12 months, Akcea Therapeutics's shares have ranged in value from as little as $8 up to $18.57. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Akcea Therapeutics's is 1.4434. This would suggest that Akcea Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Akcea Therapeutics overview

Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, an antisense medicine designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome, as well as is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of homozygous familial hypercholesterolemia; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. is a subsidiary of Ionis Pharmaceuticals, Inc.

Frequently asked questions

• What percentage of Akcea Therapeutics is owned by insiders or institutions?

  Currently 82.877% of Akcea Therapeutics shares are held by insiders and 20.842% by institutions.

• How many people work for Akcea Therapeutics?

  Latest data suggests 294 work at Akcea Therapeutics.

• When does the fiscal year end for Akcea Therapeutics?

  Akcea Therapeutics's fiscal year ends in December.

• Where is Akcea Therapeutics based?

  Akcea Therapeutics's address is: 22 Boston Wharf Road, Boston, MA, United States, 02210

• What is Akcea Therapeutics's ISIN number?

  Akcea Therapeutics's international securities identification number is: US00972L1070

• What is Akcea Therapeutics's CUSIP number?

  Akcea Therapeutics's Committee on Uniform Securities Identification Procedures number is: 00972L107